TY - JOUR
T1 - Effects of auriculin (atrial natriuretic factor) on blood pressure, renal function, and the renin-aldosterone system in dogs
AU - Maack, Thomas
AU - Marion, Donald N.
AU - Camargo, Maria Jose F.
AU - Kleinert, Hollis D.
AU - Laragh, John H.
AU - Vaughan, E. Darracott
AU - Atlas, Steven A.
N1 - Funding Information:
From the Departments of Physiology, Surgery, and Medicine and the Hypertension Center Cornell University Medical College, New York, New York. This work was supported by National Institutes of Health Grants AM-14241 and HL-18323-SCR, and by California Biotechnology Inc., Mountain View, California. Dr. Atlas was supported by National Institutes of Health Research Carrier Development Award HL-00570. Requests for reprints should be addressed to Dr. Thomas Maack, Department of Physiology, Cornell University Medical College, 1300 York Avenue, New York, New York 10021. Manuscript accepted September 20, 1984.
PY - 1984/12
Y1 - 1984/12
N2 - Auriculin is a potent vasoactive and natriuretic peptide that was recently isolated and purified from rat atrial tissue. Since this peptide could be of great importance for renal, cardiovascular, and volume homeostasis, its functional properties have been characterized in dogs. The effects of synthetic auriculin on renal function, mean blood pressure, plasma renin activity, renin secretory rate, and plasma aldosterone levels were determined. Auriculin was administered intravenously as a prime (1.0 μg/kg body weight) and constant infusion (0.1 μg per minute/kg body weight for one hour) to five anesthetized dogs. In addition, two conscious dogs were used to verify some of the results obtained in anesthetized dogs. Auriculin decreased mean blood pressure from 134 ± 5 to 122 ± 4 mm Hg (p < 0.05, paired t test) and increased glomerular filtration rate (25.5 ± 2.7 to 32.4 ± 4.1 ml per minute per kidney, p < 0.05), diuresis (0.21 ± 0.03 to 1.06 ± 0.14 ml per minute per kidney, p < 0.05), natriuresis (38 ± 0.6 to 187 ± 35 μeq per minute per kidney, p < 0.05), and kaliuresis (14.8 ± 1.6 to 35.7 ± 6.3 μeq per minute per kidney, p < 0.05). These effects were sustained throughout the infusion of auriculin and were entirely reversible. Renal plasma flow increased transiently for one to two minutes, and then returned to or below control levels. Urine osmolality decreased by 40 percent (p < 0.05) whereas free water clearance remained unchanged (p > 0.05). Auriculin reversibly decreased plasma renin activity (11.6 ± 2.3 to 3.6 ± 1.2 ng/ml per hour, p < 0.05), renin secretory rate (895 ± 313 to 255 ± 28 ng per hour per minute, p < 0.05), and plasma aldosterone levels (8.4 ± 1.6 to 3.6 ± 0.7 ng/dl, p < 0.05), whereas plasma cortisol levels remained unchanged. These results demonstrate that auriculin has a unique combination of functional properties, increasing glomerular filtration rate, diuresis, and natriuresis, without a sustained increase in total renal blood flow, and lowering blood pressure, plasma renin levels, renin secretory rate, and plasma aldosterone levels. These properties suggest an important potential role for atrial natriuretic peptides in the regulation of renal function, extracellular volume, and blood pressure.
AB - Auriculin is a potent vasoactive and natriuretic peptide that was recently isolated and purified from rat atrial tissue. Since this peptide could be of great importance for renal, cardiovascular, and volume homeostasis, its functional properties have been characterized in dogs. The effects of synthetic auriculin on renal function, mean blood pressure, plasma renin activity, renin secretory rate, and plasma aldosterone levels were determined. Auriculin was administered intravenously as a prime (1.0 μg/kg body weight) and constant infusion (0.1 μg per minute/kg body weight for one hour) to five anesthetized dogs. In addition, two conscious dogs were used to verify some of the results obtained in anesthetized dogs. Auriculin decreased mean blood pressure from 134 ± 5 to 122 ± 4 mm Hg (p < 0.05, paired t test) and increased glomerular filtration rate (25.5 ± 2.7 to 32.4 ± 4.1 ml per minute per kidney, p < 0.05), diuresis (0.21 ± 0.03 to 1.06 ± 0.14 ml per minute per kidney, p < 0.05), natriuresis (38 ± 0.6 to 187 ± 35 μeq per minute per kidney, p < 0.05), and kaliuresis (14.8 ± 1.6 to 35.7 ± 6.3 μeq per minute per kidney, p < 0.05). These effects were sustained throughout the infusion of auriculin and were entirely reversible. Renal plasma flow increased transiently for one to two minutes, and then returned to or below control levels. Urine osmolality decreased by 40 percent (p < 0.05) whereas free water clearance remained unchanged (p > 0.05). Auriculin reversibly decreased plasma renin activity (11.6 ± 2.3 to 3.6 ± 1.2 ng/ml per hour, p < 0.05), renin secretory rate (895 ± 313 to 255 ± 28 ng per hour per minute, p < 0.05), and plasma aldosterone levels (8.4 ± 1.6 to 3.6 ± 0.7 ng/dl, p < 0.05), whereas plasma cortisol levels remained unchanged. These results demonstrate that auriculin has a unique combination of functional properties, increasing glomerular filtration rate, diuresis, and natriuresis, without a sustained increase in total renal blood flow, and lowering blood pressure, plasma renin levels, renin secretory rate, and plasma aldosterone levels. These properties suggest an important potential role for atrial natriuretic peptides in the regulation of renal function, extracellular volume, and blood pressure.
UR - http://www.scopus.com/inward/record.url?scp=0021690132&partnerID=8YFLogxK
U2 - 10.1016/0002-9343(84)90190-6
DO - 10.1016/0002-9343(84)90190-6
M3 - Article
C2 - 6239544
AN - SCOPUS:0021690132
SN - 0002-9343
VL - 77
SP - 1069
EP - 1075
JO - American Journal of Medicine
JF - American Journal of Medicine
IS - 6
ER -